A Phase 3 interventional study of placebo and pegloticase in Gout, sponsored by Savient Pharmaceuticals. Completed at 56 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-28.
Sponsored by Savient Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.
Among the 14 studies testing pegloticase in Gout, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 3, and was the 3rd registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 93 across the 14 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 4 most frequent:
Savient Pharmaceuticals is the lead sponsor of 6 studies on the registry; none are open to participants now.
Savient Pharmaceuticals has 4 studies filed under Gout — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pegloticase in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard gout therapies, or for whom those therapies have been unsuccessful in controlling their uric acid level.
The primary objective of each of the studies is to demonstrate superiority in the response rate (control of uric acid levels to below 6 mg/dL) in the PEG-uricase treatment groups compared to the placebo-control group.
While reduction or resolution of tophi have been reported in the setting of prolonged urate-lowering therapy, there is photographic and additional anecdotal evidence from the Phase 2 PEG-uricase study of resolution or significant reduction of tophi after 3 months of therapy. Therefore, an assessment of changes in tophi over time will be conducted through the use of digital photographs obtained in a standardized manner from all subjects during the study. The effect on other clinical outcomes, including quality of life, health-related disability measures, gout flares and the number of swollen and tender joints will also be compared between the treatment groups and control group. Subjects will be randomized to one of the three treatment arms in a 2:2:1 ratio: 8 mg PEG-uricase every 2 weeks; 8 mg PEG-uricase every 4 weeks; or placebo. All subjects will receive an intravenous infusion (PEG-uricase or placebo) every two weeks in order to maintain the blind throughout the study. Study duration is approximately 26 weeks, including two weeks for screening and 24 weeks (6 months) of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8 mg pegloticase every 2 weeks
Biological: pegloticase
8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
Biological: pegloticase
placebo every 2 weeks
Other: placebo
placebo by intravenous infusion every 2 weeks
8 mg pegloticase by intravenous infusion
Also known as: PEG-uricase, Puricase
Plasma Uric Acid (PUA) Responder
PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations \< 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders.
Time frame: Months 3 and 6
Reduction in Tophus Burden
percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software.
Time frame: Baseline and Final Visit (6 months or LOCF)
Percentage of Subjects With Gout Flare Per 3-month Period
Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period.
Time frame: Months 1-3 and Months 4-6
Change in Number of Swollen Joints
Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies.
Time frame: Baseline and Final Visit (Month 6 or LOCF)
Change in Number of Tender Joints
Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant
Time frame: Baseline and Final Visit (Month 6 or LOCF)
Change in Patient Reported Outcomes of Pain, Physical Function and Quality of Life
Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of \> or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of \> or =2.5 units in the PCS is considered a MCID.
Time frame: Baseline to Final Visit (Month 6 or LOCF)
Rheumatology practices across the US, Canada and Mexico
| Milestone | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Started | 90 | 89 | 46 |
| Completed | 85 | 84 | 43 |
| Not completed | 5 | 5 | 3 |
| Withdrew: Not dosed | 5 | 5 | 3 |
| Milestone | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Started | 85 | 84 | 43 |
| Completed | 59 | 59 | 39 |
| Not completed | 26 | 25 | 4 |
| Withdrew: Adverse event | 15 | 17 | 1 |
| Withdrew: Death | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 6 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Protocol violation/non-compliance | 1 | 1 | 0 |
PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations \< 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders.
| Participants | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Plasma Uric Acid (PUA) Responder | 36 | 29 | 0 |
percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software.
| Percent subjects with resolved tophus | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Reduction in Tophus Burden | 40 | 21 | 7 |
Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period.
| Percent subjects reporting flares | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Months 1-3 | 75 | 81 | 54 |
| Months 4-6 | 41 | 56 | 67 |
Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies.
| Swollen joints | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Change in Number of Swollen Joints | -5.5 ± 10.47 | -5.1 ± 7.83 | -2.6 ± 11.64 |
Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant
| Tender joints | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Change in Number of Tender Joints | -7.4 ± 11.95 | -6.1 ± 10.64 | -1.2 ± 12.30 |
Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of \> or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of \> or =2.5 units in the PCS is considered a MCID.
| Units on a scale | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| HAQ-VAS Pain | -11.4 ± 33.8 | -6.9 ± 27.0 | 1.4 ± 30.0 |
| HAQ-DI | -0.22 ± 0.64 | -0.20 ± 0.55 | 0.0 ± 0.41 |
| SF-36 PCS | 4.4 ± 9.4 | 4.9 ± 8.5 | -0.3 ± 9.0 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| q2 Wks | — | 20/85 (23.5%) | 69/85 (81.2%) |
| q4 Wks | — | 19/84 (22.6%) | 79/84 (94%) |
| Placebo | — | 5/43 (11.6%) | 36/43 (83.7%) |
| Event | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Infusion Related ReactionGeneral disorders | 4/85 | 7/84 | 0/43 |
| GoutMusculoskeletal and connective tissue disorders | 4/85 | 1/84 | 2/43 |
| ArrhythmiaCardiac disorders | 2/85 | 0/84 | 0/43 |
| Gatrooesophageal Reflux DiseaseGastrointestinal disorders | 2/85 | 0/84 | 0/43 |
| PneumoniaInfections and infestations | 1/85 | 1/84 | 1/43 |
| Arthritis BacterialInfections and infestations | 0/85 | 0/84 | 1/43 |
| Herpes ZosterInfections and infestations | 0/85 | 0/84 | 1/43 |
| Perianal AbscessInfections and infestations | 0/85 | 0/84 | 1/43 |
| PancreatitisGastrointestinal disorders | 0/85 | 1/84 | 1/43 |
| Inguinal Hernia, ObstructiveGastrointestinal disorders | 0/85 | 0/84 | 1/43 |
| Event | q2 Wks | q4 Wks | Placebo |
|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 4/85 | 4/84 | 9/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/85 | 15/84 | 8/43 |
| DiarrhoeaGastrointestinal disorders | 9/85 | 14/84 | 8/43 |
| Oedema PeripheralGeneral disorders | 9/85 | 11/84 | 6/43 |
| NauseaGastrointestinal disorders | 10/85 | 6/84 | 1/43 |
| HeadacheNervous system disorders | 8/85 | 9/84 | 4/43 |
| InsomniaPsychiatric disorders | 5/85 | 8/84 | 4/43 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 3/85 | 5/84 | 4/43 |
| FatigueGeneral disorders | 5/85 | 6/84 | 4/43 |
| DizzinessNervous system disorders | 3/85 | 7/84 | 4/43 |
| Age, Categorical(Participants) | q2 Wks | q4 Wks | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 56 | 65 | 31 | 152 |
| >=65 years | 29 | 19 | 12 | 60 |
| Age Continuous(years) | q2 Wks | q4 Wks | Placebo | Total |
|---|---|---|---|---|
| Mean | 56.3 ± 15.53 | 54.5 ± 13.34 | 55.4 ± 12.21 | 55.4 ± 14.01 |
| Sex: Female, Male(Participants) | q2 Wks | q4 Wks | Placebo | Total |
|---|---|---|---|---|
| Female | 17 | 15 | 7 | 39 |
| Male | 68 | 69 | 36 | 173 |
| Region of Enrollment(participants) | q2 Wks | q4 Wks | Placebo | Total |
|---|---|---|---|---|
| United States | 73 | 77 | 39 | 189 |
| Canada | 1 | 1 | 1 | 3 |
| Mexico | 11 | 6 | 3 | 20 |
The record gives a start of May 2006, a primary completion of Oct 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegloticase
Savient Pharmaceuticals